Related references
Note: Only part of the references are listed.Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio et al.
JOURNAL OF NEUROSCIENCE (2021)
Excitotoxicity as a Target Against Neurodegenerative Processes
Octavio Binvignat et al.
CURRENT PHARMACEUTICAL DESIGN (2020)
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Danielle M. Gerhard et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Translocator protein-mediated fast-onset antidepressant-like and memory-enhancing effects in chronically stressed mice
Chao Shang et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Chronic Binge Alcohol Exposure During Pregnancy Alters mTOR System in Rat Fetal Hippocampus
Jehoon Lee et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2020)
Brain NMDA Receptors in Schizophrenia and Depression
Albert Adell
BIOMOLECULES (2020)
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)
Hazem Ahmed et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
7, 8-Dihydroxy-4-methylcoumarin reverses depression model-induced depression-like behaviors and alteration of dendritic spines in the mood circuits
Mi Yang et al.
PSYCHONEUROENDOCRINOLOGY (2020)
BDNF-induced local translation of GluA1 is regulated by HNRNP A2/B1
Youngseob Jung et al.
SCIENCE ADVANCES (2020)
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2020)
Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect
Wenyan Cui et al.
MOLECULAR NEUROBIOLOGY (2019)
Estrogen, Stress, and Depression: Cognitive and Biological Interactions
Kimberly M. Albert et al.
ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 15 (2019)
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Ronald S. Duman et al.
MOLECULAR PSYCHIATRY (2019)
Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments
Ronald S. Duman et al.
NEURON (2019)
An update on NMDA antagonists in depression
Bartlomiej Pochwat et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Ketamine and depression: a narrative review
Alexandrine Corriger et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability
Svitlana Antoniuk et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2019)
Cognitive dysfunction in major depressive disorder
Matthew J. Knight et al.
CURRENT OPINION IN PSYCHIATRY (2018)
Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling
Jessica R. Gilbert et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Mechanisms of ketamine action as an antidepressant
P. Zanos et al.
MOLECULAR PSYCHIATRY (2018)
PSD95: A synaptic protein implicated in schizophrenia or autism?
Austin A. Coley et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders
Larisa Ryskalin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Side-effects associated with ketamine use in depression: a systematic review
Brooke Short et al.
LANCET PSYCHIATRY (2018)
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice
Weronika Stasiuk et al.
JOURNAL OF NEURAL TRANSMISSION (2017)
Ketamine for Depression, 2: Diagnostic and Contextual Indications
Chittaranjan Andrade
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial
Atsuo Nakagawa et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action
Chittaranjan Andrade
JOURNAL OF CLINICAL PSYCHIATRY (2017)
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity
Yu-Jhen Huang et al.
NEURAL PLASTICITY (2017)
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine
Marc S. Lener et al.
BIOLOGICAL PSYCHIATRY (2017)
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice
Ewa Poleszak et al.
METABOLIC BRAIN DISEASE (2016)
Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice
Weronika Stasiuk et al.
PHARMACOLOGICAL REPORTS (2016)
NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism
Carly Kiselycznyk et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
G. I. Papakostas et al.
MOLECULAR PSYCHIATRY (2015)
Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice
Xiao-Long Liu et al.
SCIENTIFIC REPORTS (2015)
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li et al.
SCIENCE (2010)
Relation between outcomes and localisation of p-mTOR expression in gastric cancer
T. Murayama et al.
BRITISH JOURNAL OF CANCER (2009)
An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
Sheldon H. Preskorn et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Antidepressant effects of ketamine in depressed patients
RM Berman et al.
BIOLOGICAL PSYCHIATRY (2000)
CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents
FS Menniti et al.
NEUROPHARMACOLOGY (2000)
Share Paper
